Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Silence Therapeutics (SLN) EPS (Weighted Average and Diluted): 2018-2024

Historic EPS (Weighted Average and Diluted) for Silence Therapeutics (SLN) over the last 6 years, with Dec 2024 value amounting to -$0.33.

  • Silence Therapeutics' EPS (Weighted Average and Diluted) rose 40.00% to -$0.15 in Q3 2025 from the same period last year, while for Sep 2025 it was -$0.45, marking a year-over-year increase of 17.35%. This contributed to the annual value of -$0.33 for FY2024, which is 32.65% up from last year.
  • Per Silence Therapeutics' latest filing, its EPS (Weighted Average and Diluted) stood at -$0.33 for FY2024, which was up 32.65% from -$0.49 recorded in FY2023.
  • In the past 5 years, Silence Therapeutics' EPS (Weighted Average and Diluted) registered a high of -$0.33 during FY2024, and its lowest value of -$51.11 during FY2020.
  • Moreover, its 3-year median value for EPS (Weighted Average and Diluted) was -$0.49 (2023), whereas its average is -$0.45.
  • In the last 5 years, Silence Therapeutics' EPS (Weighted Average and Diluted) tumbled by 53.36% in 2020 and then skyrocketed by 32.65% in 2024.
  • Silence Therapeutics' EPS (Weighted Average and Diluted) (Yearly) stood at -$51.11 in 2020, then reached -$0.52 in 2022, then climbed by 5.77% to -$0.49 in 2023, then soared by 32.65% to -$0.33 in 2024.